GrantSet

Grant opportunity · PAR-24-293

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Applications close384 days leftAug 18, 2027
AgencyNational Institutes of Health
CategoryDiscretionary
Assistance listing93.121,93.867,93.279,93.242,93.113,93.853,93.273,93.213,93.866
OpensOct 1, 2024
ClosesAug 18, 2027
Award floor
Award ceiling
Expected awardsNot stated

Who can apply (as listed)

  • City or township governments
  • Public and state-controlled institutions of higher education
  • Private institutions of higher education
  • Independent school districts
  • Small businesses
  • Special district governments
  • Native American tribal governments (federally recognized)
  • Public housing authorities / Indian housing authorities
  • State governments
  • Nonprofits without 501(c)(3) status (other than institutions of higher education)
  • For-profit organizations (other than small businesses)
  • Others (see the opportunity text)
  • Native American tribal organizations (other than federally recognized governments)
  • Nonprofits with 501(c)(3) status (other than institutions of higher education)
  • County governments
From the listing

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and ther…

Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.

GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.